IN PARTNERSHIP
Clinical trials are changing, along with support requirements
Clinical trials have always been pivotal to medical research – without the proof of efficacy, tolerance and safety they provide, no new drug or procedure can come safely to market.
C
linical trials have always relied on being methodical, painstaking and accurate – meaning doubt cannot be cast on
the results they generate. But the COVID-19 pandemic transformed everything. Suddenly, the clinical trial landscape changed, and it became increasingly difficult for scientists and study managers to invite trial participants to attend traditional clinical trial sites. Scientists might still be working in laboratories,
but traditional access to trial study cohorts became complicated by the need to follow COVID-19 safety guidelines. Some trials were changed, many trials were paused, and others were abandoned altogether. But the new reality has taken the previously modest trend towards remote clinical trials into overdrive, with COVID-19 seeing some 45% of sites switch participants to remote trial solutions. And when decentralised clinical trials become, for
24 | Outsourcing in Clinical Trials Handbook
many, the new norm, the choice of outsourcing supply partners grows increasingly critical. What are the key considerations for success here?
Reduced control drives the need for greater supplier confidence At Avantor, we’ve been supporting clinical trials of all kinds in all corners of the world for many years now. That means we know first-hand the challenges of remote clinical trials and how to overcome them. As a key partner to 10 out of the world’s top 10 pharma companies and nine out of the world’s top 10 clinical research organisations, Avantor has built its reputation not only by meeting but by anticipating the needs of organisations like yours.
While it is reassuring to find a global partner with the experience and expertise to support all types of clinical trials, it is also worth noting that every trial is different. Each one comes with its
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100